Tiago Fauth
Stock Analyst at Wells Fargo
(1.00)
# 2,751
Out of 4,479 analysts
105
Total ratings
26.37%
Success rate
-19.89%
Average return
Main Sectors:
Top Industries:
29 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $161 → $207 | $243.32 | -14.93% | 3 | Jun 25, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Equal-Weight | $35 → $2 | $1.70 | +17.65% | 2 | Jun 18, 2024 | |
| UTHR United Therapeutics | Maintains: Overweight | $325 → $350 | $319.01 | +9.71% | 3 | Jun 12, 2024 | |
| INZY Inozyme Pharma | Initiates: Overweight | $14 | $4.41 | +217.46% | 1 | May 30, 2024 | |
| INSM Insmed | Maintains: Overweight | $55 → $77 | $66.34 | +16.07% | 2 | May 29, 2024 | |
| WVE Wave Life Sciences | Initiates: Overweight | $11 | $5.24 | +110.12% | 1 | May 15, 2024 | |
| KROS Keros Therapeutics | Initiates: Overweight | $60 | $43.77 | +37.08% | 1 | Dec 8, 2023 | |
| RARE Ultragenyx Pharmaceutical | Initiates: Overweight | $72 | $41.12 | +75.10% | 5 | Dec 8, 2023 | |
| VTYX Ventyx Biosciences | Maintains: Outperform | $63 → $62 | $2.26 | +2,643.36% | 5 | Aug 11, 2023 | |
| ASND Ascendis Pharma | Assumes: Neutral | $89 | $133.98 | -33.57% | 14 | Jun 14, 2023 | |
| VRDN Viridian Therapeutics | Assumes: Outperform | $51 | $13.21 | +286.07% | 3 | Jun 14, 2023 | |
| BMRN BioMarin Pharmaceutical | Assumes: Outperform | $120 | $82.13 | +46.11% | 7 | Jun 14, 2023 | |
| ME 23andMe Holding Co. | Reiterates: Outperform | $6 | $0.38 | +1,494.90% | 6 | May 26, 2023 | |
| IMVT Immunovant | Reiterates: Underperform | $4 | $27.51 | -85.46% | 4 | May 23, 2023 | |
| ABSI Absci | Reiterates: Outperform | $14 | $3.01 | +365.12% | 4 | May 16, 2023 | |
| SPRB Spruce Biosciences | Reiterates: Outperform | $4 | $0.53 | +653.44% | 3 | May 16, 2023 | |
| KURA Kura Oncology | Reiterates: Outperform | $26 | $21.20 | +22.64% | 5 | May 11, 2023 | |
| ABCL AbCellera Biologics | Maintains: Outperform | $34 → $28 | $2.78 | +907.19% | 7 | May 5, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $70 → $81 | $36.29 | +123.20% | 9 | May 5, 2023 | |
| BCAB BioAtla | Reiterates: Neutral | $8 | $1.35 | +492.59% | 4 | Mar 24, 2023 | |
| PYXS Pyxis Oncology | Reiterates: Outperform | $14 | $3.20 | +337.50% | 2 | Mar 23, 2023 | |
| ALXO ALX Oncology Holdings | Maintains: Outperform | $38 → $34 | $5.99 | +467.61% | 2 | Mar 10, 2023 | |
| GLTO Galecto | Reiterates: Outperform | $6 | $0.47 | +1,187.28% | 2 | Mar 10, 2023 | |
| EXEL Exelixis | Initiates: Outperform | $29 | $22.25 | +30.34% | 1 | Jan 26, 2023 | |
| OABI OmniAb | Initiates: Outperform | $13 | $3.74 | +247.59% | 1 | Dec 16, 2022 | |
| EDIT Editas Medicine | Downgrades: Neutral | $25 → $13 | $4.61 | +182.00% | 2 | Nov 18, 2022 | |
| IFRX InflaRx | Maintains: Underperform | $2.5 → $2 | $1.72 | +16.28% | 3 | May 13, 2022 | |
| ARGX argenx SE | Maintains: Neutral | n/a | $434.22 | - | 2 | Dec 20, 2021 | |
| AMGN Amgen | Maintains: Outperform | n/a | $311.01 | - | 1 | Apr 28, 2021 |
Alnylam Pharmaceuticals
Jun 25, 2024
Maintains: Equal-Weight
Price Target: $161 → $207
Current: $243.32
Upside: -14.93%
Aerovate Therapeutics
Jun 18, 2024
Downgrades: Equal-Weight
Price Target: $35 → $2
Current: $1.70
Upside: +17.65%
United Therapeutics
Jun 12, 2024
Maintains: Overweight
Price Target: $325 → $350
Current: $319.01
Upside: +9.71%
Inozyme Pharma
May 30, 2024
Initiates: Overweight
Price Target: $14
Current: $4.41
Upside: +217.46%
Insmed
May 29, 2024
Maintains: Overweight
Price Target: $55 → $77
Current: $66.34
Upside: +16.07%
Wave Life Sciences
May 15, 2024
Initiates: Overweight
Price Target: $11
Current: $5.24
Upside: +110.12%
Keros Therapeutics
Dec 8, 2023
Initiates: Overweight
Price Target: $60
Current: $43.77
Upside: +37.08%
Ultragenyx Pharmaceutical
Dec 8, 2023
Initiates: Overweight
Price Target: $72
Current: $41.12
Upside: +75.10%
Ventyx Biosciences
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $2.26
Upside: +2,643.36%
Ascendis Pharma
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $133.98
Upside: -33.57%
Viridian Therapeutics
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $13.21
Upside: +286.07%
BioMarin Pharmaceutical
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $82.13
Upside: +46.11%
23andMe Holding Co.
May 26, 2023
Reiterates: Outperform
Price Target: $6
Current: $0.38
Upside: +1,494.90%
Immunovant
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $27.51
Upside: -85.46%
Absci
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $3.01
Upside: +365.12%
Spruce Biosciences
May 16, 2023
Reiterates: Outperform
Price Target: $4
Current: $0.53
Upside: +653.44%
Kura Oncology
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $21.20
Upside: +22.64%
AbCellera Biologics
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $2.78
Upside: +907.19%
Apellis Pharmaceuticals
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $36.29
Upside: +123.20%
BioAtla
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $1.35
Upside: +492.59%
Pyxis Oncology
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $3.20
Upside: +337.50%
ALX Oncology Holdings
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $5.99
Upside: +467.61%
Galecto
Mar 10, 2023
Reiterates: Outperform
Price Target: $6
Current: $0.47
Upside: +1,187.28%
Exelixis
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $22.25
Upside: +30.34%
OmniAb
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $3.74
Upside: +247.59%
Editas Medicine
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $4.61
Upside: +182.00%
InflaRx
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $1.72
Upside: +16.28%
argenx SE
Dec 20, 2021
Maintains: Neutral
Price Target: n/a
Current: $434.22
Upside: -
Amgen
Apr 28, 2021
Maintains: Outperform
Price Target: n/a
Current: $311.01
Upside: -